29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs) - European Lung Cancer Congress 2019

29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1^st or 2^nd generation EGFR tyrosine kinase inhibitors (TKIs)

Translational research

29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1^st or 2^nd generation EGFR tyrosine kinase inhibitors (TKIs)

Authors

O. Juan Vidal (Valencia, Spain)
J. Simarro (Valencia, Spain)
D. Lorente Estelles (Valencia, Spain)
G. Pérez-Simó (Valencia, Spain)
N. Mancheno (Valencia, Spain)
R. Murria (Valencia, Spain)
J. Gomez Codina (Valencia, Spain)
B. Laiz (Valencia, Spain)
S. Palanca (Valencia, Spain)

Speakers

O. Juan Vidal (Valencia, Spain)

Previous ePoster

24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation

Next ePosters

30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer

31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer

33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy

35P - Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population

36P - Can a BALF profile distinguish hot vs cold lung tumors?

38P - Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells

41P - Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis

44P - Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative

45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative

46P - Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative